---
document_datetime: 2025-12-09 23:18:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ontozry.html
document_name: ontozry.html
version: success
processing_time: 0.106478
conversion_datetime: 2025-12-28 18:01:47.683971
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ontozry

[RSS](/en/individual-human-medicine.xml/67424)

##### Authorised

This medicine is authorised for use in the European Union

cenobamate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ontozry](#news-on)
- [More information on Ontozry](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ontozry is an epilepsy medicine for treating epileptic fits starting in one specific part of the brain (focal seizures), including those that eventually spread to the whole brain (secondary generalisation).

Ontozry is used as an add-on to other epilepsy medicines for adults with seizures that are not controlled despite having tried at least two other treatments.

It contains the active substance cenobamate.

Expand section

Collapse section

## How is Ontozry used?

Ontozry is available as tablets taken once daily. The patient starts with a daily dose of 12.5 mg and the dose increases over several weeks up to a target of 200 mg. If the patient's seizures are still not controlled, the dose may increase to up 400 mg.

The medicine can only be obtained with a prescription. For more information about using Ontozry, see the package leaflet or contact your doctor or pharmacist.

## How does Ontozry work?

Epilepsy is caused by abnormal electrical activity in the brain. The exact way in which Ontorzy works is unclear but it affects the activity of channels that allow electrical impulses to be transmitted between nerve cells. This may prevent abnormal electrical activity in the brain, reducing the chance of an epileptic fit.

## What benefits of Ontozry have been shown in studies?

In a main study involving 437 patients Ontorzy was more effective than placebo (a dummy treatment) at lowering the number of seizures in patients with uncontrolled partial seizures despite past treatment. Around 40% of patients who took a 100 mg daily dose of Ontorzy during 3 months of treatment and 64% of those who took a 400 mg daily dose had at least a 50% drop in the frequency of their seizures. This compares with 26% of patients taking placebo.

## What are the risks associated with Ontozry?

The most common side effects with Ontozry (which may affect more than 1 in 10 people) are sleepiness, headache and problems with keeping balance.

Ontozry should not be used by patients with familial short QT syndrome, a rare genetic condition that can lead to irregular heart rhythm. For the full list of restrictions and side effects, see the package leaflet.

## Why is Ontozry authorised in the EU?

A main study showed that Ontozry can reduce the frequency of seizures in many patients. The side effects that occur most frequently are those that affect the nervous system such as sleepiness, tiredness and dizziness.

The European Medicines Agency concluded that Ontozry's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ontozry?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ontozry have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ontozry are continuously monitored. Side effects reported with Ontozry are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ontozry

Ontozry received a marketing authorisation valid throughout the EU on 26 March 2021.

Ontozry : EPAR - Medicine overview

Reference Number: EMA/103317/2021

English (EN) (117.31 KB - PDF)

**First published:** 13/04/2021

[View](/en/documents/overview/ontozry-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-831)

български (BG) (139.9 KB - PDF)

**First published:**

13/04/2021

[View](/bg/documents/overview/ontozry-epar-medicine-overview_bg.pdf)

español (ES) (117.36 KB - PDF)

**First published:**

13/04/2021

[View](/es/documents/overview/ontozry-epar-medicine-overview_es.pdf)

čeština (CS) (137.13 KB - PDF)

**First published:**

13/04/2021

[View](/cs/documents/overview/ontozry-epar-medicine-overview_cs.pdf)

dansk (DA) (116.57 KB - PDF)

**First published:**

13/04/2021

[View](/da/documents/overview/ontozry-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.66 KB - PDF)

**First published:**

13/04/2021

[View](/de/documents/overview/ontozry-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.29 KB - PDF)

**First published:**

13/04/2021

[View](/et/documents/overview/ontozry-epar-medicine-overview_et.pdf)

ελληνικά (EL) (139.95 KB - PDF)

**First published:**

13/04/2021

[View](/el/documents/overview/ontozry-epar-medicine-overview_el.pdf)

français (FR) (118.43 KB - PDF)

**First published:**

13/04/2021

[View](/fr/documents/overview/ontozry-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.08 KB - PDF)

**First published:**

13/04/2021

[View](/hr/documents/overview/ontozry-epar-medicine-overview_hr.pdf)

italiano (IT) (116.26 KB - PDF)

**First published:**

13/04/2021

[View](/it/documents/overview/ontozry-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (145.44 KB - PDF)

**First published:**

13/04/2021

[View](/lv/documents/overview/ontozry-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.7 KB - PDF)

**First published:**

13/04/2021

[View](/lt/documents/overview/ontozry-epar-medicine-overview_lt.pdf)

magyar (HU) (135.35 KB - PDF)

**First published:**

13/04/2021

[View](/hu/documents/overview/ontozry-epar-medicine-overview_hu.pdf)

Malti (MT) (140.45 KB - PDF)

**First published:**

13/04/2021

[View](/mt/documents/overview/ontozry-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.76 KB - PDF)

**First published:**

13/04/2021

[View](/nl/documents/overview/ontozry-epar-medicine-overview_nl.pdf)

polski (PL) (140.32 KB - PDF)

**First published:**

13/04/2021

[View](/pl/documents/overview/ontozry-epar-medicine-overview_pl.pdf)

português (PT) (117.86 KB - PDF)

**First published:**

13/04/2021

[View](/pt/documents/overview/ontozry-epar-medicine-overview_pt.pdf)

română (RO) (136.66 KB - PDF)

**First published:**

13/04/2021

[View](/ro/documents/overview/ontozry-epar-medicine-overview_ro.pdf)

slovenčina (SK) (137.43 KB - PDF)

**First published:**

13/04/2021

[View](/sk/documents/overview/ontozry-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.5 KB - PDF)

**First published:**

13/04/2021

[View](/sl/documents/overview/ontozry-epar-medicine-overview_sl.pdf)

Suomi (FI) (126 KB - PDF)

**First published:**

13/04/2021

[View](/fi/documents/overview/ontozry-epar-medicine-overview_fi.pdf)

svenska (SV) (116.29 KB - PDF)

**First published:**

13/04/2021

[View](/sv/documents/overview/ontozry-epar-medicine-overview_sv.pdf)

Ontozry : EPAR - Risk-management-plan

English (EN) (1.25 MB - PDF)

**First published:** 13/04/2021

**Last updated:** 23/04/2024

[View](/en/documents/rmp/ontozry-epar-risk-management-plan_en.pdf)

## Product information

Ontozry : EPAR - Product information

English (EN) (712.68 KB - PDF)

**First published:** 13/04/2021

**Last updated:** 03/12/2025

[View](/en/documents/product-information/ontozry-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-918)

български (BG) (646.98 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/bg/documents/product-information/ontozry-epar-product-information_bg.pdf)

español (ES) (651.25 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/es/documents/product-information/ontozry-epar-product-information_es.pdf)

čeština (CS) (607.15 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/cs/documents/product-information/ontozry-epar-product-information_cs.pdf)

dansk (DA) (612.76 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/da/documents/product-information/ontozry-epar-product-information_da.pdf)

Deutsch (DE) (618.14 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/de/documents/product-information/ontozry-epar-product-information_de.pdf)

eesti keel (ET) (583.85 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/et/documents/product-information/ontozry-epar-product-information_et.pdf)

ελληνικά (EL) (670.13 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/el/documents/product-information/ontozry-epar-product-information_el.pdf)

français (FR) (600.93 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/fr/documents/product-information/ontozry-epar-product-information_fr.pdf)

hrvatski (HR) (649.4 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/hr/documents/product-information/ontozry-epar-product-information_hr.pdf)

íslenska (IS) (583.25 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/is/documents/product-information/ontozry-epar-product-information_is.pdf)

italiano (IT) (669.26 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/it/documents/product-information/ontozry-epar-product-information_it.pdf)

latviešu valoda (LV) (618.1 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/lv/documents/product-information/ontozry-epar-product-information_lv.pdf)

lietuvių kalba (LT) (601.97 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/lt/documents/product-information/ontozry-epar-product-information_lt.pdf)

magyar (HU) (658.85 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/hu/documents/product-information/ontozry-epar-product-information_hu.pdf)

Malti (MT) (674.34 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/mt/documents/product-information/ontozry-epar-product-information_mt.pdf)

Nederlands (NL) (595.36 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/nl/documents/product-information/ontozry-epar-product-information_nl.pdf)

norsk (NO) (599.18 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/no/documents/product-information/ontozry-epar-product-information_no.pdf)

polski (PL) (685.8 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/pl/documents/product-information/ontozry-epar-product-information_pl.pdf)

português (PT) (628.28 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/pt/documents/product-information/ontozry-epar-product-information_pt.pdf)

română (RO) (675.81 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/ro/documents/product-information/ontozry-epar-product-information_ro.pdf)

slovenčina (SK) (675.65 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/sk/documents/product-information/ontozry-epar-product-information_sk.pdf)

slovenščina (SL) (650.19 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/sl/documents/product-information/ontozry-epar-product-information_sl.pdf)

Suomi (FI) (616.26 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/fi/documents/product-information/ontozry-epar-product-information_fi.pdf)

svenska (SV) (620.03 KB - PDF)

**First published:**

13/04/2021

**Last updated:**

03/12/2025

[View](/sv/documents/product-information/ontozry-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000273504 17/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ontozry : EPAR - All authorised presentations

English (EN) (56.34 KB - PDF)

**First published:** 13/04/2021

[View](/en/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-646)

български (BG) (64.83 KB - PDF)

**First published:**

13/04/2021

[View](/bg/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_bg.pdf)

español (ES) (59.33 KB - PDF)

**First published:**

13/04/2021

[View](/es/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.68 KB - PDF)

**First published:**

13/04/2021

[View](/cs/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.91 KB - PDF)

**First published:**

13/04/2021

[View](/da/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (58.66 KB - PDF)

**First published:**

13/04/2021

[View](/de/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (51.41 KB - PDF)

**First published:**

13/04/2021

[View](/et/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.41 KB - PDF)

**First published:**

13/04/2021

[View](/el/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_el.pdf)

français (FR) (50.85 KB - PDF)

**First published:**

13/04/2021

[View](/fr/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.11 KB - PDF)

**First published:**

13/04/2021

[View](/hr/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (52.12 KB - PDF)

**First published:**

13/04/2021

[View](/is/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_is.pdf)

italiano (IT) (53.64 KB - PDF)

**First published:**

13/04/2021

[View](/it/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (54.71 KB - PDF)

**First published:**

13/04/2021

[View](/lv/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (54.11 KB - PDF)

**First published:**

13/04/2021

[View](/lt/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (52.98 KB - PDF)

**First published:**

13/04/2021

[View](/hu/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (54.87 KB - PDF)

**First published:**

13/04/2021

[View](/mt/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (50.8 KB - PDF)

**First published:**

13/04/2021

[View](/nl/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (51.01 KB - PDF)

**First published:**

13/04/2021

[View](/no/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.81 KB - PDF)

**First published:**

13/04/2021

[View](/pl/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.93 KB - PDF)

**First published:**

13/04/2021

[View](/pt/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.27 KB - PDF)

**First published:**

13/04/2021

[View](/ro/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.85 KB - PDF)

**First published:**

13/04/2021

[View](/sk/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.74 KB - PDF)

**First published:**

13/04/2021

[View](/sl/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.58 KB - PDF)

**First published:**

13/04/2021

[View](/fi/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (52.63 KB - PDF)

**First published:**

13/04/2021

[View](/sv/documents/all-authorised-presentations/ontozry-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ontozry Active substance cenobamate International non-proprietary name (INN) or common name cenobamate Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

## Authorisation details

EMA product number EMEA/H/C/005377

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Angelini Pharma S.p.A

Angelini Pharma S.p.A

Marketing authorisation issued 26/03/2021 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ontozry : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (162.26 KB - PDF)

**First published:** 08/04/2025

**Last updated:** 03/12/2025

[View](/en/documents/procedural-steps-after/ontozry-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ontozry : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (172.04 KB - PDF)

**First published:** 02/06/2021

**Last updated:** 08/04/2025

[View](/en/documents/procedural-steps-after/ontozry-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Ontozry-H-C-PSUSA-00010921-202303 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/505768/2023

English (EN) (102.32 KB - PDF)

**First published:** 18/01/2024

[View](/en/documents/scientific-conclusion/ontozry-h-c-psusa-00010921-202303-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ontozry : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/160820/2021

English (EN) (4 MB - PDF)

**First published:** 13/04/2021

[View](/en/documents/assessment-report/ontozry-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ontozry

Adopted

Reference Number: EMA/CHMP/12859/2021

English (EN) (137.76 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ontozry_en.pdf)

#### News on Ontozry

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

#### More information on Ontozry

- [EMEA-002563-PIP02-19-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002563-pip02-19-m03)

**This page was last updated on** 03/12/2025

## Share this page

[Back to top](#main-content)